The current standard of care for the treatment of anal cancer as demonstrated by all of the completed phase 3 clinical trials remains 5-FU and mitomycin C in combination with radiation therapy. The basic elements of the approach outlined by Nigro have not changed in the last 30 years. Future phase 3 trials will serve to further perfect this approach and outline the role of HPV and dysplasia in the development and progression of this disease.
|Original language||English (US)|
|Number of pages||6|
|Journal||Surgical Oncology Clinics of North America|
|State||Published - Apr 2004|
ASJC Scopus subject areas